JPH0456600B2 - - Google Patents

Info

Publication number: JPH0456600B2
Authority: JP; Japan
Prior art keywords: group; medium; component; streptococci; reagent
Prior art date: 1984-02-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

JP314985A

Other languages

English (en)

Japanese (ja)

Other versions

JPS60176599A (ja

Inventor

Eru Ebansu Jooji

Ii Oniiru Teresa

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Becton Dickinson and Co

Original Assignee

Becton Dickinson and Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-02-21

Filing date

1985-01-11

Publication date

1992-09-08

1985-01-11 Application filed by Becton Dickinson and Co filed Critical Becton Dickinson and Co

1985-09-10 Publication of JPS60176599A publication Critical patent/JPS60176599A/ja

1992-09-08 Publication of JPH0456600B2 publication Critical patent/JPH0456600B2/ja

Status Granted legal-status Critical Current

Links

239000002609 medium Substances 0.000 claims description 29
239000003153 chemical reaction reagent Substances 0.000 claims description 28
244000005700 microbiome Species 0.000 claims description 15
229940124530 sulfonamide Drugs 0.000 claims description 13
150000003456 sulfonamides Chemical class 0.000 claims description 13
241001505901 Streptococcus sp. 'group A' Species 0.000 claims description 12
206010018910 Haemolysis Diseases 0.000 claims description 10
108010040201 Polymyxins Proteins 0.000 claims description 9
229940126575 aminoglycoside Drugs 0.000 claims description 9
229960001082 trimethoprim Drugs 0.000 claims description 9
IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims description 9
238000000034 method Methods 0.000 claims description 8
239000013078 crystal Substances 0.000 claims description 7
239000000203 mixture Substances 0.000 claims description 7
229960005404 sulfamethoxazole Drugs 0.000 claims description 7
JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical group O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 claims description 7
108010078777 Colistin Proteins 0.000 claims description 6
230000008588 hemolysis Effects 0.000 claims description 6
229930193140 Neomycin Natural products 0.000 claims description 5
229960001127 colistin sulfate Drugs 0.000 claims description 5
239000001963 growth medium Substances 0.000 claims description 5
ZESIAEVDVPWEKB-ORCFLVBFSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O ZESIAEVDVPWEKB-ORCFLVBFSA-N 0.000 claims description 5
229960004927 neomycin Drugs 0.000 claims description 5
229940041153 polymyxins Drugs 0.000 claims description 5
229930182566 Gentamicin Natural products 0.000 claims description 4
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 4
NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 claims description 4
229960004821 amikacin Drugs 0.000 claims description 4
LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims description 4
229960002518 gentamicin Drugs 0.000 claims description 4
229960000318 kanamycin Drugs 0.000 claims description 4
229930027917 kanamycin Natural products 0.000 claims description 4
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 4
229930182823 kanamycin A Natural products 0.000 claims description 4
SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 claims description 4
229960004306 sulfadiazine Drugs 0.000 claims description 4
229960000654 sulfafurazole Drugs 0.000 claims description 4
238000012360 testing method Methods 0.000 claims description 4
229960000707 tobramycin Drugs 0.000 claims description 4
NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims description 4
238000012258 culturing Methods 0.000 claims description 2
235000015097 nutrients Nutrition 0.000 claims 2
239000007789 gas Substances 0.000 description 31
108010001478 Bacitracin Proteins 0.000 description 12
229960003071 bacitracin Drugs 0.000 description 12
229930184125 bacitracin Natural products 0.000 description 12
CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 12
239000008280 blood Substances 0.000 description 12
210000004369 blood Anatomy 0.000 description 12
241000894006 Bacteria Species 0.000 description 11
210000003800 pharynx Anatomy 0.000 description 10
241001494479 Pecora Species 0.000 description 6
239000006161 blood agar Substances 0.000 description 6
230000002949 hemolytic effect Effects 0.000 description 6
241000193996 Streptococcus pyogenes Species 0.000 description 5
239000004615 ingredient Substances 0.000 description 5
229920001817 Agar Polymers 0.000 description 4
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
239000008272 agar Substances 0.000 description 4
239000003242 anti bacterial agent Substances 0.000 description 4
238000011081 inoculation Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 3
244000068988 Glycine max Species 0.000 description 3
235000010469 Glycine max Nutrition 0.000 description 3
239000001888 Peptone Substances 0.000 description 3
108010080698 Peptones Proteins 0.000 description 3
241000295644 Staphylococcaceae Species 0.000 description 3
241000194017 Streptococcus Species 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
230000000845 anti-microbial effect Effects 0.000 description 3
229940088710 antibiotic agent Drugs 0.000 description 3
239000005018 casein Substances 0.000 description 3
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
235000021240 caseins Nutrition 0.000 description 3
238000001514 detection method Methods 0.000 description 3
239000000499 gel Substances 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
235000019319 peptone Nutrition 0.000 description 3
235000021395 porridge Nutrition 0.000 description 3
239000006152 selective media Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
241000588653 Neisseria Species 0.000 description 2
108090000526 Papain Proteins 0.000 description 2
239000004365 Protease Substances 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
239000001569 carbon dioxide Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
210000001819 pancreatic juice Anatomy 0.000 description 2
229940055729 papain Drugs 0.000 description 2
235000019834 papain Nutrition 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
238000012344 serological confirmation Methods 0.000 description 2
230000000405 serological effect Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
241000894007 species Species 0.000 description 2
-1 sulfamethoxazole Chemical class 0.000 description 2
229940006995 sulfamethoxazole and trimethoprim Drugs 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
IIZVTUWSIKTFKO-UHFFFAOYSA-N 2-hydroxypropanoic acid;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound CC(O)C(O)=O.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IIZVTUWSIKTFKO-UHFFFAOYSA-N 0.000 description 1
241000195576 Bacillus subtilis group Species 0.000 description 1
229920000298 Cellophane Polymers 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
241000186660 Lactobacillus Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
241000194105 Paenibacillus polymyxa Species 0.000 description 1
201000007100 Pharyngitis Diseases 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
206010039587 Scarlet Fever Diseases 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
241000256215 Spongomorpha aeruginosa Species 0.000 description 1
238000013019 agitation Methods 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000000721 bacterilogical effect Effects 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000035602 clotting Effects 0.000 description 1
ZXJXZNDDNMQXFV-UHFFFAOYSA-M crystal violet Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1[C+](C=1C=CC(=CC=1)N(C)C)C1=CC=C(N(C)C)C=C1 ZXJXZNDDNMQXFV-UHFFFAOYSA-M 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical class CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
229960001235 gentian violet Drugs 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
238000002955 isolation Methods 0.000 description 1
229940039696 lactobacillus Drugs 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Polymers CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
YKQOSKADJPQZHB-YNWHQGOSSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1s)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Polymers CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O YKQOSKADJPQZHB-YNWHQGOSSA-N 0.000 description 1
229960000210 nalidixic acid Drugs 0.000 description 1
MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
OIXVKQDWLFHVGR-WQDIDPJDSA-N neomycin B sulfate Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO OIXVKQDWLFHVGR-WQDIDPJDSA-N 0.000 description 1
229940053050 neomycin sulfate Drugs 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
125000001477 organic nitrogen group Chemical group 0.000 description 1
244000045947 parasite Species 0.000 description 1
229940066779 peptones Drugs 0.000 description 1
239000002985 plastic film Substances 0.000 description 1
229920006255 plastic film Polymers 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002028 premature Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
239000008213 purified water Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
201000003068 rheumatic fever Diseases 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
230000001629 suppression Effects 0.000 description 1
229960001937 trimethoprim lactate Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
- C12Q1/14—Streptococcus; Staphylococcus
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/315—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Streptococcus (G), e.g. Enterococci

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Toxicology (AREA)
Immunology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

JP314985A 1984-02-21 1985-01-11 Ａ群連鎖球菌に対する選択試薬 Granted JPS60176599A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US58194384A	1984-02-21	1984-02-21
US581943		1990-09-13

Publications (2)

Publication Number	Publication Date
JPS60176599A JPS60176599A (ja)	1985-09-10
JPH0456600B2 true JPH0456600B2 (fr)	1992-09-08

Family

ID=24327209

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP314985A Granted JPS60176599A (ja)	1984-02-21	1985-01-11	Ａ群連鎖球菌に対する選択試薬

Country Status (4)

Country	Link
JP (1)	JPS60176599A (fr)
CA (1)	CA1205029A (fr)
DE (1)	DE3505311C2 (fr)
GB (1)	GB2154606B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2003290377A1 (en) *	2003-01-03	2004-07-29	Marton Milankovits	Pharmaceutical compositions comprising an antibacterial agent nd antifungal agent and a nitroimidazole for the treatment and prevention of genitourinary infections and their extragenital complications
SK287315B6 (sk)	2006-06-02	2010-06-07	Biotika, A. S.	Spôsob izolácie polymyxínu B z vyfermentovanej pôdy
SK287293B6 (sk)	2006-06-15	2010-05-07	Biotika, A. S.	Spôsob fermentácie polymyxínu B pomocou produkčného mikroorganizmu Bacillus polymyxa
JP5118336B2 (ja) *	2006-11-28	2013-01-16	日水製薬株式会社	腸球菌検出用培地

1984
- 1984-11-16 CA CA000467966A patent/CA1205029A/fr not_active Expired
- 1984-11-27 GB GB08429863A patent/GB2154606B/en not_active Expired
1985
- 1985-01-11 JP JP314985A patent/JPS60176599A/ja active Granted
- 1985-02-15 DE DE19853505311 patent/DE3505311C2/de not_active Expired

Also Published As

Publication number	Publication date
DE3505311C2 (de)	1987-05-07
JPS60176599A (ja)	1985-09-10
GB8429863D0 (en)	1985-01-03
CA1205029A (fr)	1986-05-27
GB2154606A (en)	1985-09-11
GB2154606B (en)	1987-03-25
DE3505311A1 (de)	1985-12-19

Publication	Publication Date	Title
Guttier et al.	1971	Effect of rifampin and minocycline on meningococcal carrier rates
Heimdahl et al.	1980	Isolation of β-lactamase-producing Bacteroides strains associated with clinical failures with penicillin treatment of human orofacial infections
Bantar et al.	1996	Species belonging to the" Streptococcus milleri" group: antimicrobial susceptibility and comparative prevalence in significant clinical specimens
Baker	1984	Comparison of various methods for differentiation of staphylococci and micrococci
Gilligan et al.	1987	Prevalence of thymidine-dependent Staphylococcus aureus in patients with cystic fibrosis
van Horn et al.	1996	Selective isolation of vancomycin-resistant enterococci
US7632657B2 (en)	2009-12-15	Method of detecting meticillin-resistant microorganisms
Yajko et al.	1987	Broth microdilution testing of susceptibilities to 30 antimicrobial agents of Mycobacterium avium strains from patients with acquired immune deficiency syndrome
Males et al.	1975	Virulence factors of biotypes of Staphylococcus epidermidis from clinical sources
US20100047852A1 (en)	2010-02-25	Selective culture medium
AU5006096A (en)	1996-10-16	Method and culture medium for identification of salmonellae
Boyce et al.	1985	Nosocomial pneumonia caused by a glucose-metabolizing strain of Neisseria cinerea
Bartoov et al.	1991	Virulence characteristics of male genital tract Escherichia coll isolated from semen of suspected infertile men
Wilkins et al.	1976	Medium-dependent inhibition of Peptostreptococcus anaerobius by sodium polyanetholsulfonate in blood culture media
US20040235012A1 (en)	2004-11-25	Method of detecting antibiotic resistance in microorganisms
JPH0456600B2 (fr)	1992-09-08
JPH07181A (ja)	1995-01-06	多剤耐性ブドウ球菌を選択的に培養するための培地
KR101824588B1 (ko)	2018-02-01	메티실린-저항성 ｓ. 아우레우스의 스크리닝 또는 농축을 위한 배양 배지
JP2000116399A (ja)	2000-04-25	薬剤感受性菌・薬剤耐性菌鑑別用分画培地および鑑別方法
Blackwell et al.	1975	Frequency and some properties of clinical isolates of methicillin-resistant Staphylococcus aureus
La Zonby et al.	1986	Screening method for recovery of methicillin-resistant Staphylococcus aureus from primary plates
Olsson-Liljequist et al.	1993	Introducing fosfomycin for surgical prophylaxis-emergence of resistance in aerobic faecal gram-negative bacteria of in-patients, but not among strains causing infection after elective colorectal procedures
Dierksen et al.	2000	A new alkaline pH-adjusted medium enhances detection of β-hemolytic streptococci by minimizing bacterial interference due to Streptococcus salivarius
JP3380956B2 (ja)	2003-02-24	黄色ブドウ球菌の検出培地
US6165776A (en)	2000-12-26	Selective and differential medium for isolation of Listeria Monocytogenes